Drug Trial Radar · NCT06431607
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
845
Actual
Start
May 23, 2024
Primary completion
Dec 27, 2024
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
Conditions
- Influenza, Human
Interventions
F2G22B/DL001ZBiological
Study intervention was administered intramuscularly at Day 1.
F2H23D/DL001Z-NHBiological
Study intervention was administered intramuscularly at Day 1.
F2H23B/DL001Z-NHBiological
Study intervention was administered intramuscularly at Day 1.
F2H23H/DL001ZBiological
Study intervention was administered intramuscularly at Day 1.
FDQ23A-NH (Flu D-QIV)Combination product
Control Vaccine was administered intramuscularly at Day 1.
GSK5800544ABiological
Study intervention was administered intramuscularly at Day 1.
Flu D-TIVCombination product
Control Vaccine was administered intramuscularly at Day 1.
F2H23A/DL001Z-NHBiological
Study intervention was administered intramuscularly at Day 1.
F2H23G/DL001ZBiological
Study intervention was administered intramuscularly at Day 1.
Fluzone HD QuadrivalentCombination product
Control vaccine was administered intramuscularly at Day 1.
Fluzone HDCombination product
Control vaccine was administered intramuscularly at Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 YA: Geometric Mean Titer (GMT) of Antigen 1 Antibody TiterTime frame: At Day 29
- Part 2 YA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
- Part 1 OA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
- Part 2 OA: GMT of Antigen 1 Antibody TiterTime frame: At Day 29
- Part 1 YA: Geometric Mean Increase (GMI) of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
- Part 2 YA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
- Part 1 OA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
- Part 2 OA: GMI of Antigen 1 Antibody TitersTime frame: From Day 1 (baseline) to Day 29
- Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroconversion Rate (SCR)Time frame: From Day 1 (baseline) to Day 29
- Part 2 YA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
- Part 1 OA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
- Part 2 OA: Percentage of Participants With Antigen 1 Antibody SCRTime frame: From Day 1 (baseline) to Day 29
- Part 1 YA: Percentage of Participants With Antigen 1 Antibody Seroprotection Rate (SPR)Time frame: At Day 1
- Part 2 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
- Part 1 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
- Part 2 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 1
- Part 1 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
- Part 2 YA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
- Part 1 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
- Part 2 OA: Percentage of Participants With Antigen 1 Antibody SPRTime frame: At Day 29
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Valparaiso, Indiana
GSK Investigational Site
El Dorado, Kansas
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Newton, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Knoxville, Tennessee
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Tomball, Texas
GSK Investigational Site
Newport News, Virginia
GSK Investigational Site
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.